Pink crisis, clear solution: how advanced mass spectrometry turned a manufacturing risk into success
Learn how KBI Biopharma used advanced mass spectrometry to address a cell culture media issue and prevent a potential manufacturing disruption.
CDMO
- Latest Posts
Accelerating the path to clinical filing applications with rapid toxicology material delivery
Pre-clinical toxicology studies and prompt material delivery are essential for IND and CTA approvals, crucial for advancing drug candidates to clinical trials.
News and Trends 28 Aug 2024
GLP-1 shortage: Can biotech companies keep up with rising demand?
How is the biotech industry responding to the GLP-1 drug shortage? We asked experts in the field to answer this question.
Expert Advice 19 Jul 2024
The ABC of biotech partnerships
Discover eight different types of biotech partnerships, including what each one entails and its advantages and disadvantages.
How a microbial expression update is driving biotech innovation
Discover how microbial expression systems are revolutionizing protein production for next-gen therapies like antibodies and peptides.
More News! 11 Jul 2024
CDMO trends post-Wuxi’s exit from the US: who will take its place?
The BIOSECURE Act is reshuffling the deck and Indian CDMOs are looking good. Discover the trends in this evolving landscape.
ADVERTISEMENT
ADVERTISEMENT
Powering up biologics development using mammalian cell lines
Explore how mammalian cell lines drive biopharmaceutical innovation, acting as mini-factories for vital biotherapeutics and vaccines.
News and Trends 18 Apr 2024
Biotech under surveillance: The global impact of the WuXi AppTec controversy
Delve into the ongoing controversy involving the Chinese company WuXi AppTec and the possible impact on U.S. national security measures.
Expert Advice 5 Apr 2024
How to build a career as an investigator at the FDA?
Discover the role and implications of an FDA investigator, a career of high responsibility and challenges, from qualifications to application.
In Depth 27 Feb 2024
Can the Novo Holdings-Catalent deal set a new standard for Pharma M&A?
Explore the strategic implications of Novo Nordisk’s $16.5B Catalent acquisition on drug supply and market competition.
Why Fina Biosolutions partnered with Scorpius BioManufacturing for cGMP production of EcoCRM® (CRM197)
Explore Fina Biosolutions’ alliance with Scorpius BioManufacturing, driving affordability in global conjugate vaccine production.
Mastering biologics tech transfer: key success factors
Unlock the secrets of efficient tech transfers for biologics, and explore critical stages and success factors.
ADVERTISEMENT